A bumped kinase inhibitor for use in a treatment of an apicomplexan protozoan related disease, wherein the inhibitor is of the formula, or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are defined by either: (i) X is N, Y is C, and Z is N; or (ii) X is C, Y is N, and Z is C; R 1 is C 1-4 alkyl or -C 1-4 alkyl-R 12, wherein R 12 is -OR, -SR, -NR 2, -C R, -C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R, -N C OR, -N C NR 2, phenyl, monocyclic heteroaryl, C 3-8 cycloalkyl, or monocyclic heterocyclyl, wherein the phenyl, heteroaryl, C 3-8 cycloalkyl, and heterocyclyl groups are each optionally substituted by one, two, or three groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, -OR, -SR, -NR 2, -C R,-C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R,-N C OR, or -N C NR 2; L is a bond or -CH 2 -; R 3 is naphthyl, quinolinyl, indolyl, benzodioxolyl, 2,3-dihydrobenzodioxinyl, or chromanyl, each optionally substituted with one, two, or three R 31 groups, wherein each R 31 is independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, arylC 1-6 alkyl, heteroarylC 1-6 alkyl, -OR, -SR, -NR 2, -C R, -C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R, -N C OR, -N C NR 2 or -N S 2 R, wherein the aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, arylalkyl, and heteroarylalkyl groups are optionally substituted with one or two R 10 groups; each R is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four R 10 groups; and each R 10 is independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, -OR 0, -SR 0, -N(R 0) 2, -C R 0, -C OR 0, -C N(R 0) 2, -S 2 R 0, -OC R 0, -OC OR 0, -OC N(R 0) 2, -N(R 0)C R 0, -N(R 0)C OR 0, or -N(R 0)C N(R 0) 2, wherein each R 0 is independently hydrogen or C 1-6 alkyl. X, Y, and Z are defined by either: (i) X is N, Y is C, and Z is N; or (ii) X is C, Y is N, and Z is C; R 1 is C 1-4 alkyl or -C 1-4 alkyl-R 12, wherein R 12 is -OR, -SR, -NR 2, -C R, -C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R, -N C OR, -N C NR 2, phenyl, monocyclic heteroaryl, C 3-8 cycloalkyl, or monocyclic heterocyclyl, wherein the phenyl, heteroaryl, C 3-8 cycloalkyl, and heterocyclyl groups are each optionally substituted by one, two, or three groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, -OR, -SR, -NR 2, -C R,-C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R,-N C OR, or -N C NR 2; R 12 is -OR, -SR, -NR 2, -C R, -C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R, -N C OR, -N C NR 2, phenyl, monocyclic heteroaryl, C 3-8 cycloalkyl, or monocyclic heterocyclyl, wherein the phenyl, heteroaryl, C 3-8 cycloalkyl, and heterocyclyl groups are each optionally substituted by one, two, or three groups that are each independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, -OR, -SR, -NR 2, -C R,-C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R,-N C OR, or -N C NR 2; L is a bond or -CH 2 -; R 3 is naphthyl, quinolinyl, indolyl, benzodioxolyl, 2,3-dihydrobenzodioxinyl, or chromanyl, each optionally substituted with one, two, or three R 31 groups, wherein each R 31 is independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, arylC 1-6 alkyl, heteroarylC 1-6 alkyl, -OR, -SR, -NR 2, -C R, -C OR, -C NR 2, -S 2 R, -OC R, -OC OR, -OC NR 2, -N C R, -N C OR, -N C NR 2 or -N S 2 R, wherein the aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, arylalkyl, and heteroarylalkyl groups are optionally substituted with one or two R 10 groups; each R is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four R 10 groups; and each R is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, arylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four R 10 groups; each R 10 is independently halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, -OR 0, -SR 0, -N(R 0) 2, -C R 0, -C OR 0, -C N(R 0) 2, -S 2 R 0, -OC R 0, -OC OR 0, -OC N(R 0) 2, -N(R 0)C R 0, -N(R 0)C OR 0, or -N(R 0)C N(R 0) 2, wherein each R 0 is independently hydrogen or C 1-6 alkyl.